FR22C1013I2 - Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives - Google Patents

Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives

Info

Publication number
FR22C1013I2
FR22C1013I2 FR22C1013C FR22C1013C FR22C1013I2 FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2 FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 C FR22C1013 C FR 22C1013C FR 22C1013 I2 FR22C1013 I2 FR 22C1013I2
Authority
FR
France
Prior art keywords
dihydronaphtyridines
treatment
kinase inhibitors
compounds useful
related compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1013C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deciphera Pharmaceuticals LLC
Original Assignee
Deciphera Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals LLC filed Critical Deciphera Pharmaceuticals LLC
Publication of FR22C1013I1 publication Critical patent/FR22C1013I1/fr
Application granted granted Critical
Publication of FR22C1013I2 publication Critical patent/FR22C1013I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
FR22C1013C 2012-06-07 2022-04-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives Active FR22C1013I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17208408.9A EP3366293B1 (fr) 2012-06-07 2012-06-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives
PCT/US2012/041378 WO2013184119A1 (fr) 2012-06-07 2012-06-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives

Publications (2)

Publication Number Publication Date
FR22C1013I1 FR22C1013I1 (fr) 2022-06-17
FR22C1013I2 true FR22C1013I2 (fr) 2022-12-30

Family

ID=49712374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1013C Active FR22C1013I2 (fr) 2012-06-07 2022-04-07 Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives

Country Status (28)

Country Link
EP (3) EP3366293B1 (fr)
JP (1) JP5883195B2 (fr)
KR (1) KR101652229B1 (fr)
CN (3) CN104902895B (fr)
AU (1) AU2012327210B2 (fr)
BR (1) BR112014030577B1 (fr)
CA (1) CA2875970C (fr)
CY (1) CY1123377T1 (fr)
DK (2) DK2858646T3 (fr)
ES (2) ES2663605T3 (fr)
FR (1) FR22C1013I2 (fr)
HR (1) HRP20200864T1 (fr)
HU (2) HUE049958T2 (fr)
IL (1) IL236110A (fr)
LT (2) LT3366293T (fr)
LU (1) LUC00253I2 (fr)
MX (2) MX392372B (fr)
NL (1) NL301169I2 (fr)
NO (1) NO2022010I1 (fr)
PH (2) PH12018502294B1 (fr)
PL (1) PL3366293T3 (fr)
PT (2) PT2858646T (fr)
RS (1) RS60406B1 (fr)
RU (1) RU2664055C2 (fr)
SG (1) SG11201408133TA (fr)
SI (1) SI3366293T1 (fr)
SM (1) SMT202000302T1 (fr)
WO (1) WO2013184119A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP3943087A1 (fr) 2013-03-15 2022-01-26 Celgene CAR LLC Composés hétéroaryle et utilisations associées
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
MX382436B (es) * 2016-01-11 2025-03-13 Merck Patent Gmbh Derivados de quinolin-2-ona.
MY205552A (en) * 2017-05-30 2024-10-25 Deciphera Pharmaceuticals Inc Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha
WO2019056990A1 (fr) * 2017-09-20 2019-03-28 浙江海正药业股份有限公司 Dérivé de 1,2-dihydro-1,6-naphtyridine, son procédé de préparation et son application en médecine
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
CN118416236A (zh) * 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2020185812A1 (fr) * 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Formes à l'état solide de riprétinib
TW202106684A (zh) 2019-05-03 2021-02-16 美商奇奈特生物製藥公司 Raf激酶抑制劑
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (fr) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib pour le traitement de tumeurs stromales gastro-intestinales
TW202126306A (zh) * 2019-10-04 2021-07-16 美商纜圖藥品公司 嗜酸性球性病症之治療
JP7626910B2 (ja) 2019-10-24 2025-02-05 ピエール ファーブル メディカモン Ｒａｆキナーゼの阻害剤
EP4084779B1 (fr) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
WO2022060996A1 (fr) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibiteurs de raf kinases
WO2022081469A1 (fr) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibiteurs de kinases raf
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (fr) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Procédé de préparation de riprétinib et de formes à l'état solide de celui-ci
BR112023021913A2 (pt) 2021-04-23 2024-01-16 Kinnate Biopharma Inc Tratamento de câncer com inibidor de raf
WO2023122322A1 (fr) * 2021-12-24 2023-06-29 Teva Pharmaceuticals International Gmbh Procédés améliorés pour la préparation de ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
EP4472968A1 (fr) 2022-02-03 2024-12-11 Pierre Fabre Medicament Inhibiteurs de raf kinases
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
CN101553232A (zh) * 2006-09-14 2009-10-07 迪赛孚尔制药有限公司 用于治疗增殖性疾病的激酶抑制剂
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008051757A1 (fr) * 2006-10-20 2008-05-02 Irm Llc Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr)
EA018551B1 (ru) * 2008-02-22 2013-08-30 Айрм Ллк ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-KIT И PDGFR

Also Published As

Publication number Publication date
KR20150053894A (ko) 2015-05-19
CN104902895B (zh) 2019-03-29
NO2022010I1 (no) 2022-04-07
IL236110A0 (en) 2015-01-29
RU2664055C2 (ru) 2018-08-14
RU2014153920A (ru) 2016-07-27
RS60406B1 (sr) 2020-07-31
MX372814B (es) 2020-07-03
CY1123377T1 (el) 2021-12-31
NL301169I2 (nl) 2026-03-02
CN110433162A (zh) 2019-11-12
BR112014030577A8 (pt) 2018-10-23
DK2858646T3 (en) 2018-03-19
BR112014030577B1 (pt) 2022-02-08
HRP20200864T1 (hr) 2020-08-21
ES2663605T3 (es) 2018-04-16
PT3366293T (pt) 2020-06-18
AU2012327210A1 (en) 2014-01-09
CA2875970A1 (fr) 2013-12-12
LUC00253I2 (fr) 2025-03-04
HUE049958T2 (hu) 2020-11-30
EP3722296A3 (fr) 2020-10-21
MX392372B (es) 2025-03-24
LTPA2022008I1 (fr) 2022-05-25
JP5883195B2 (ja) 2016-03-09
EP2858646A4 (fr) 2015-09-02
WO2013184119A1 (fr) 2013-12-12
KR101652229B1 (ko) 2016-08-30
PH12014502757B1 (en) 2015-03-02
IL236110A (en) 2016-11-30
PT2858646T (pt) 2018-03-27
HUS2200017I1 (hu) 2022-06-28
LT3366293T (lt) 2020-07-10
PH12018502294A1 (en) 2020-11-04
FR22C1013I1 (fr) 2022-06-17
SMT202000302T1 (it) 2020-07-08
DK3366293T3 (da) 2020-06-15
CN104902895A (zh) 2015-09-09
LTC3366293I2 (fr) 2024-11-25
MX2014015024A (es) 2015-07-06
EP2858646B1 (fr) 2017-12-20
ES2797252T3 (es) 2020-12-01
PH12018502294B1 (en) 2024-02-28
PL3366293T3 (pl) 2020-09-21
CN110403938A (zh) 2019-11-05
AU2012327210B2 (en) 2016-07-28
EP2858646A1 (fr) 2015-04-15
EP3366293A1 (fr) 2018-08-29
EP3366293B1 (fr) 2020-03-11
PH12014502757A1 (en) 2015-03-02
SG11201408133TA (en) 2015-01-29
JP2015520186A (ja) 2015-07-16
HK1209345A1 (en) 2016-04-01
MX2020005712A (es) 2022-05-17
CA2875970C (fr) 2017-07-04
SI3366293T1 (sl) 2020-08-31
EP3722296A2 (fr) 2020-10-14

Similar Documents

Publication Publication Date Title
FR22C1013I2 (fr) Dihydronaphtyridines et composés apparentés utiles comme inhibiteurs de kinases pour le traitement de maladies prolifératives
FR19C1062I2 (fr) Derives macrocycliques pour le traitement de maladies proliferatives
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
EP2925740A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
IL244492A0 (en) Broton tyrosine kinase inhibitors
EP2988743A4 (fr) Composés hétérocycliques utilisés pour le traitement de maladies
EP2852579A4 (fr) Composés pyrimidines pour le traitement du cancer
EP2766352A4 (fr) Composés indazole utilisés comme inhibiteurs de kinase et méthode de traitement du cancer avec lesdits composés
IL282112A (en) Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
EP2858500A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP2773342A4 (fr) Compositions utiles pour le traitement de maladies virales
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
ME03078B (fr) Dérivés de sulfonylpipéridine et leur utilisation pour le traitement de maladies médiées par une prokinéticine
EP2863748A4 (fr) Inhibiteurs de 1,2,4-triazine-6-carboxamide kinase
EP2968321A4 (fr) Composés pour le traitement de maladies de fibrose
EP2976340A4 (fr) Cycloalkylnitrile pyrazolopyridones utilisées comme inhibiteurs de la janus kinase
EP2833886A4 (fr) Quinoléines substituées en tant qu'inhibiteurs de tyrosine kinases de bruton
EP2825173A4 (fr) Inhibiteurs de calmoduline pour le traitement de troubles ribosomiques et de ribosomapathies
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP2922534A4 (fr) Méthodes et compositions pour le traitement de maladies neurodégénératives
EP2895504A4 (fr) Agonistes de trpv3 pour le traitement de maladies cutanées
EP2544686A4 (fr) Procédés combinés pour le traitement de maladies